A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Latest action (28 Sep 2026): Introduced
What this bill does
This bill, S. 5571, introduced by Senator Marsha Blackburn, aims to change the rules for when biosimilar drugs can be included in price negotiations for the Medicare program. Biosimilar drugs are approved by the Food and Drug Administration (FDA) and are similar to existing biologic drugs, often offering a lower-cost alternative. The bill specifically addresses the timing of when these biosimilar products become eligible for negotiation under Medicare.
The specific details of how this bill would alter the eligibility timeline for biosimilar price negotiations are not yet available, as the full text of the bill has not been published. However, it would affect the Medicare program by potentially changing the conditions under which certain prescription drugs could have their prices negotiated, impacting both the cost of these medications and the options available to beneficiaries.
Currently, S. 5571 has just been introduced in the Senate. As an introduced bill, it has not yet undergone any committee review or floor debate. For it to potentially become law, it would need to pass both the Senate and the House of Representatives in identical form and then be signed by the President.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
This bill is in the first stage of the legislative process. It was introduced into Congress on September 28, 2026. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.
Common questions
- What does S. 5571 do?
- This bill, S. 5571, introduced by Senator Marsha Blackburn, aims to change the rules for when biosimilar drugs can be included in price negotiations for the Medicare program. Biosimilar drugs are approved by the Food and Drug Administration (FDA) and are similar to existing biologic drugs, often offering a lower-cost alternative. The bill specifically addresses the timing of when these biosimilar products become eligible for negotiation under Medicare. The specific details of how this bill would alter the eligibility timeline for biosimilar price negotiations are not yet available, as the full text of the bill has not been published. However, it would affect the Medicare program by potentially changing the conditions under which certain prescription drugs could have their prices negotiated, impacting both the cost of these medications and the options available to beneficiaries. Currently, S. 5571 has just been introduced in the Senate. As an introduced bill, it has not yet undergone any committee review or floor debate. For it to potentially become law, it would need to pass both the Senate and the House of Representatives in identical form and then be signed by the President.
- Has S. 5571 become law?
- Not yet. As of 28 Sep 2026, S. 5571 is introduced.
- Who sponsored S. 5571?
- S. 5571 was sponsored by Sen. Marsha Blackburn [R-TN] (Republican-TN), with 0 cosponsors.
- What's the latest action on S. 5571?
- Introduced (28 Sep 2026).
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.